Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001213900-21-009598
Filing Date
2021-02-16
Accepted
2021-02-16 16:10:22
Documents
3
Group Members
ABIR RAVEH

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13D ea135725-13da2rimon_wize.htm SC 13D/A 61928
2 AGREEMENT DATED AS OF DECEMBER 24, 2020, BY AND BETWEEN WIZE PHARMA, INC. AND CE ea135725ex1-rimon_wize.htm EX-1 16700
3 GRAPHIC image_001.jpg GRAPHIC 3355
  Complete submission text file 0001213900-21-009598.txt   85041
Mailing Address 24 HANAGAR ST HOD HASHARON L3 4527713
Business Address 24 HANAGAR ST HOD HASHARON L3 4527713 972 472 260 0536
Wize Pharma, Inc. (Subject) CIK: 0001218683 (see all company filings)

EIN.: 880445167 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-82946 | Film No.: 21638381
SIC: 2834 Pharmaceutical Preparations

Mailing Address RAVEN RAVID & CO. 32A HABARZEL ST. TEL AVIV L3 6971047
Business Address RAVEN RAVID & CO. 32A HABARZEL ST. TEL AVIV L3 6971047 972-3-7676999
Rimon Gold Assets Ltd (Filed by) CIK: 0001721808 (see all company filings)

EIN.: 514819424
Type: SC 13D/A